Endorepellin/Perlecan/Heparan Sulfate Proteoglycan Antibody (A7L6), Novus Biologicals™

Endorepellin/Perlecan/Heparan Sulfate Proteoglycan

0.2mg/mL

Flow Cytometry, Immunohistochemistry (Paraffin), SDS-Page, Immunofluorescence

Unconjugated

Rat

Human, Mouse, Porcine, Fish, Monkey

P98160

3339

Murine EHS laminin preparation

Primary

Store at 4C.

A7L6

Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 1 - 2 ug/ml, SDS-Page, Immunofluorescence 0.5 - 1.0 ug/ml

Monoclonal

Purified

RUO

10mM PBS and 0.05% BSA with 0.05% Sodium Azide

basement membrane-specific heparan sulfate proteoglycan core protein, endorepellin (domain V region), heparan sulfate proteoglycan 2, HSPG, perlecan, perlecan proteoglycan, PLCSchwartz-Jampel syndrome 1 (chondrodystrophic myotonia), PRCAN, SJA, SJS, SJS1

HSPG2

IgG2a κ

Protein A or G purified

This MAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.